Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17137145 | 0.89 | MPL (0.44) | KDM4EALDH1A1HPGDHSD17B10NPSR1 | |
| SCHEMBL30497380 | 0.89 | MPL (0.44) | KDM4EALDH1A1HPGDHSD17B10NPSR1 | |
| SCHEMBL13442164 | 0.81 | SLC6A3 (0.43) | KDM4EALDH1A1HSD17B10KMT2AMAPT | |
| SCHEMBL9216610 | 0.80 | KDM4E (0.74) | KDM4EALDH1A1HPGDHSD17B10NPSR1 | |
| SCHEMBL26020274 | 0.77 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10NPSR1 | |
| SCHEMBL8203011 | 0.74 | ALDH1A1 (0.58) | KDM4EALDH1A1HPGDHSD17B10NPSR1 | |
| SCHEMBL29215297 | 0.73 | TSHR (0.46) | ALDH1A1HSD17B10POLBMEN1KMT2A | |
| SCHEMBL30311488 | 0.73 | TSHR (0.46) | ALDH1A1HSD17B10POLBMEN1KMT2A | |
| SCHEMBL17137307 | 0.73 | KDM4E (0.57) | KDM4EALDH1A1HPGDHSD17B10NPSR1 | |
| SCHEMBL13442165 | 0.72 | HSD17B10 (0.37) | KDM4EALDH1A1HPGDHSD17B10NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER (US) | 2023-10-26 | — | — | US | disclosed |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2020-12-03 | — | — | US | disclosed |
| CN-106458912-B | Bicyclic fused heteroaryl or aryl compounds and their use as IRAK4 mimetics | 辉瑞公司 | 2020-10-27 | — | — | CN | disclosed |
| US-10793579-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-3536685-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | Pfizer Inc (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190270751-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10329302-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180127432-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9879022-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2018-01-30 | — | — | US | disclosed |
| EP-3126330-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | Pfizer Inc (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20160347760-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-9458168-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2016-10-04 | — | — | US | disclosed |
| WO-2015150995-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150284405-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347760-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | KDM4E 3965/4885ALDH1A1 594/4885HPGD 2124/4885 |
| US-20150284405-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | KDM4E 3965/4885ALDH1A1 594/4885HPGD 2124/4885 |
| US-20190270751-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | KDM4E 3965/4885ALDH1A1 594/4885HPGD 2124/4885 |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | KDM4E 3965/4885ALDH1A1 594/4885HPGD 2124/4885 |
| US-10793579-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | KDM4E 3965/4885ALDH1A1 594/4885HPGD 2124/4885 |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | TTR, TYR, ABL1 | KDM4E 2785/4885ALDH1A1 1068/4885HPGD 2400/4885 |
| US-10329302-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | KDM4E 3965/4885ALDH1A1 594/4885HPGD 2124/4885 |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | TTR, TYR, ABL1 | KDM4E 2785/4885ALDH1A1 1068/4885HPGD 2400/4885 |
| US-20180127432-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | KDM4E 3965/4885ALDH1A1 594/4885HPGD 2124/4885 |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | KDM4E 3965/4885ALDH1A1 594/4885HPGD 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.